Search Results

BioVersys AG announced the expansion of its strategic collaboration with the global biopharma company GSK plc to accelerate the clinical development of alpibectir for the treatment of tuberculosis.

BioVersys AG announced that it has received a non-dilutive award from the CF AMR Syndicate of up to £ 500,000, via a LifeArc funded Collaborative Discovery Programme award, to support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease in people with cystic fibrosis.

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

OpGen, Inc. and BioVersys AG today announced the signing of a collaboration agreement for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.

Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.